Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CHRS

Coherus Biosciences Inc

Dec 08 • 04:00PM ET

2.22

Dollar change -0.08
Percentage change -3.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	4.73%	Shs Outstand	111.36M	Perf Week	-3.48%
Market Cap	247.22M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-4.06%	Shs Float	106.10M	Perf Month	9.36%
Income	-217.11M	PEG	-	EPS next Q	-0.32	Inst Own	86.18%	Short Float / Ratio	20.44% / 4.94	Perf Quarter	-56.04%
Sales	211.07M	P/S	1.17	EPS this Y	43.99%	Inst Trans	-1.24%	Short Interest	21.69M	Perf Half Y	-59.04%
Book/sh	-1.22	P/B	-	EPS next Y	73.31%	ROA	-38.27%	Target Price	10.62	Perf Year	-66.57%
Cash/sh	1.18	P/C	1.88	EPS next 5Y	-	ROE	-1657.06%	52W Range	1.43 - 10.99	Perf YTD	-71.97%
Dividend	-	P/FCF	-	EPS past 5Y	3.45%	ROI	-63.74%	52W High	-79.80%	Beta	0.61
Dividend %	-	Quick Ratio	1.58	Sales past 5Y	-26.62%	Gross Margin	55.87%	52W Low	55.23%	ATR	0.26
Employees	359	Current Ratio	1.85	Sales Q/Q	64.16%	Oper. Margin	-85.70%	RSI (14)	45.52	Volatility	8.40% 11.85%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	63.61%	Profit Margin	-102.86%	Rel Volume	0.62	Prev Close	2.30
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 06 AMC	Payout	-	Avg Volume	4.39M	Price	2.22
Recom	1.80	SMA20	10.28%	SMA50	-21.56%	SMA200	-54.06%	Volume	2,707,365	Change	-3.48%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54
Oct-19-16	Initiated	Robert W. Baird	Outperform	$40

Show Previous Ratings

Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Loading…
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:13PM	Coherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net Revenue (GuruFocus.com)
04:43PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:07PM	Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-03-23 08:30AM	Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +8.73%
Nov-02-23 08:00PM	Coherus BioSciences to Participate at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-23 06:00PM	Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +14.02%
05:43PM	Why Coherus BioSciences Stock Soared Today (Motley Fool)
03:07PM	Loading…
Oct-27-23 03:07PM	Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Oct-24-23 07:41PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Oct-14-23 12:30PM	Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-11-23 10:42AM	Load Up, Says Citigroup, About These 2 Strong Buy Stocks (TipRanks)
Oct-09-23 09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks)
Oct-05-23 04:45PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +9.46%
08:30AM	Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ONBODY (GlobeNewswire)
Oct-04-23 08:30AM	CIMERLI (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch (GlobeNewswire) -5.37%
Oct-02-23 09:00AM	Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day (GlobeNewswire)
Sep-27-23 09:10AM	Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-26-23 10:53AM	Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down (Zacks)
Sep-25-23 08:30AM	FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections (GlobeNewswire) -9.19%
Sep-22-23 09:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.73%
Sep-08-23 09:05AM	Coherus Completes Surface Oncology Acquisition (GlobeNewswire)
08:31AM	Why Coherus BioSciences Stock Was Plunging This Week (Motley Fool)
06:51PM	Loading…
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
04:01PM	Coherus BioSciences to Participate at Upcoming September Investor Conferences (GlobeNewswire)
Aug-31-23 04:01PM	Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote FOR the Proposed Merger with Coherus BioSciences (GlobeNewswire)
Aug-22-23 05:35PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Aug-03-23 07:43PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +17.74%
Aug-02-23 05:15PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q2 Earnings Snapshot (AP Finance)
04:01PM	Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-26-23 04:05PM	Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023 (GlobeNewswire)
Jul-21-23 05:30PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Jul-20-23 04:04PM	Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors (GlobeNewswire)
Jul-13-23 08:30AM	Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY (GlobeNewswire)
Jul-03-23 08:52AM	UPDATE 1-Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira (Reuters)
08:30AM	Coherus Launches YUSIMRY, a Biosimilar of Humira®, at $995 per Carton in U.S. (GlobeNewswire)
Jun-26-23 09:08PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Jun-21-23 08:00PM	CHRS: Rating decreased to a SELL (Argus Research)
Jun-16-23 10:00AM	Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M (Benzinga) -23.38%
08:30AM	This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? (Motley Fool)
07:01AM	Coherus to Acquire Surface Oncology (GlobeNewswire)
Jun-15-23 01:24PM	AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry (Benzinga)
10:49AM	UPDATE 1-Coherus resolves part of dispute with AbbVie over Humira biosimilar (Reuters)
07:07AM	Abbvie, Coherus agree to resolve dispute over Humira biosimilar (Reuters)
Jun-06-23 01:34PM	Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients (Benzinga) +5.82%
Jun-05-23 05:30PM	Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma (GlobeNewswire) +11.91%
09:46AM	Even Mark Cuban Cant Fix This Broken Drug System (The Wall Street Journal)
Jun-01-23 09:37AM	UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount (Reuters)
09:07AM	Coherus BioSciences to launch Humira biosimilar at $995 per carton (Reuters)
08:33AM	Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA® biosimilar, available to patients (GlobeNewswire)
08:30AM	Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY (adalimumab-aqvh) Launching in July 2023 (GlobeNewswire)
May-31-23 01:34PM	UPDATE 1-FDA flags issues at Coherus partner's China manufacturing site for cancer drug (Reuters)
01:13PM	REFILE-FDA flags issues at Coherus partner's China manufacturing site for cancer drug (Reuters)
May-22-23 08:30AM	Coherus Announces U.S. Launch of UDENYCA® Autoinjector (GlobeNewswire)
May-16-23 06:50AM	Coherus Prices Public Offering of Common Stock (GlobeNewswire) +5.93%
May-15-23 04:01PM	Coherus Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-13-23 08:11AM	News Flash: 8 Analysts Think Coherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Are Under Threat (Simply Wall St.)
May-09-23 12:48PM	Q1 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -27.40%
May-08-23 05:25PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.30%
04:05PM	Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 04:30PM	Coherus BioSciences to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-01-23 04:07PM	Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire) +6.09%
Apr-27-23 08:05AM	Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-26-23 08:00PM	CHRS: Lowering target price to $6.00 (Argus Research)
Apr-17-23 06:51AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Held Back By Insufficient Growth Even After Shares Climb 30% (Simply Wall St.)
Apr-14-23 02:45PM	The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit. (Barrons.com)
Mar-29-23 03:30AM	6 analyst picks: Lululemon sparkles \| Pro Recap (Investing.com)
Mar-27-23 11:38AM	Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 64% over the last three years (Simply Wall St.)
Mar-08-23 06:59AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.48%
Mar-07-23 11:32AM	Q4 2022 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.83%
Mar-06-23 05:15PM	Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
08:00AM	FDA Approves UDENYCA® Autoinjector (GlobeNewswire)
Mar-01-23 08:25AM	Coherus BioSciences to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-28-23 08:25AM	Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (GlobeNewswire)
Feb-15-23 08:25AM	Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (GlobeNewswire)
Feb-13-23 08:25AM	Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services (GlobeNewswire)
Feb-03-23 05:30PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) -5.25%
Jan-30-23 05:57PM	'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy' (American City Business Journals)
Jan-09-23 08:20AM	Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma (GlobeNewswire) -6.26%
Jan-04-23 07:01AM	Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.98%
Jan-03-23 07:12AM	Should You Invest in Coherus BioSciences (CHRS)? (Insider Monkey) +7.45%
Dec-25-22 08:16AM	Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Dec-24-22 12:01AM	Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Dec-21-22 06:52AM	With 74% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns (Simply Wall St.)
Nov-10-22 06:18AM	Coherus BioSciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +11.70%
Nov-08-22 05:25PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update (GlobeNewswire)
Nov-01-22 07:30AM	Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022 (GlobeNewswire)
Oct-18-22 10:48AM	Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 55% over the last three years (Simply Wall St.)
Oct-12-22 07:30AM	Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology (GlobeNewswire)
Oct-10-22 11:49AM	Will Coherus BioSciences (CHRS) Stock Bounce Back? (Insider Monkey)

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lanfear Dennis M	President & CEO	Nov 22	Option Exercise	1.42	299,940	425,015	954,793	Nov 24 04:04 PM
Lanfear Dennis M	President & CEO	Nov 22	Sale	2.02	223,100	449,770	731,693	Nov 24 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRS

Coherus Biosciences Inc

Upgrade your FINVIZ experience